CSJ117

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 1

A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

CompletedNCT03138811

Novartis PharmaceuticalsAsthma

Start: 2017-12-18End: 2019-07-16Updated: 2021-10-12

Phase 2

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

TerminatedNCT04410523

Novartis PharmaceuticalsAsthma

Start: 2020-09-09End: 2022-09-06Updated: 2024-06-20

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

CompletedNCT04882124

Novartis PharmaceuticalsPulmonary Disease, Chronic Obstructive

Start: 2021-09-24End: 2022-09-15Updated: 2022-11-28

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

TerminatedNCT04946318

Novartis PharmaceuticalsAsthma

Start: 2021-09-08End: 2022-09-08Updated: 2022-10-10